Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 3/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | HTR7 | P34969 | 2/20 | 0.35 |
| ▸ | HTR6 | P50406 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7630645 | 0.84 | SLC6A2 (0.48) | TAAR1SLC6A2SLC6A4SLC6A3DHODH | |
| SCHEMBL31517195 | 0.84 | SLC6A2 (0.48) | TAAR1SLC6A2SLC6A4SLC6A3DHODH | |
| SCHEMBL30520633 | 0.83 | SLC6A2 (0.61) | TAAR1IDO1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3243108 | 0.83 | TAAR1 (0.50) | TAAR1IDO1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL623309 | 0.83 | SLC6A2 (0.61) | TAAR1IDO1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6683911 | 0.77 | GABRA1 (0.52) | TAAR1IDO1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2010659 | 0.76 | TAAR1 (0.43) | TAAR1IDO1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3047458 | 0.76 | TAAR1 (0.56) | TAAR1SLC6A2SLC6A4SLC6A3DHODH | |
| SCHEMBL6681327 | 0.76 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3DHODHHTR2A | |
| SCHEMBL10996592 | 0.75 | TAAR1 (0.50) | TAAR1IDO1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744810-B2 | Methods of treating or preventing an attention disorder, cognitive disorder, and/or dementia associated with a neurodegenerative disorder | DREXEL UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| US-9861594-B2 | Treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder | DREXEL UNIVERSITY (US) | 2018-01-09 | — | — | US | disclosed |
| US-20170246128-A1 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | UNIV DREXEL (US) | 2017-08-31 | — | — | US | disclosed |
| US-20160256417-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | DREXEL UNIVERSITY (US) | 2016-09-08 | — | — | US | disclosed |
| US-9289400-B2 | D3 dopamine receptor agonists to treat dyskinesia in parkinson's disease | DREXEL UNIVERSITY (US) | 2016-03-22 | — | — | US | disclosed |
| US-20140228355-A1 | Novel D3 Dopamine Receptor Agonists to Treat Dyskinesia in Parkinson's Disease | UNIVERSITY OF MEDICINE AND DENTISTRY NEW JERSEY MEDICAL SCHOOL (US) | 2014-08-14 | — | — | US | disclosed |
| US-7618978-B2 | Amides as BACE inhibitors | ELI LILLY AND COMPANY (US) | 2009-11-17 | — | — | US | disclosed |
| US-20070225372-A1 | Amides as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
| EP-1740573-A1 | AMIDES AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005108391-A1 | AMIDES AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225372-A1 | Amides as Bace Inhibitors | BACE2, BACE1, APP | TAAR1 900/4885IDO1 2524/4885SLC6A2 1513/4885 |
| US-20160256417-A1 | NOVEL TREATMENTS FOR ATTENTION AND COGNITIVE DISORDERS, AND FOR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER | CHAT, BDNF, SLC18A3 | TAAR1 355/4885IDO1 1637/4885SLC6A2 13/4885 |
| US-20170246128-A1 | NOVEL D3 DOPAMINE RECEPTOR AGONISTS TO TREAT DYSKINESIA IN PARKINSON'S DISEASE | DRD3, PARK7, SLC6A3 | TAAR1 206/4885IDO1 523/4885SLC6A2 128/4885 |
| US-20140228355-A1 | Novel D3 Dopamine Receptor Agonists to Treat Dyskinesia in Parkinson's Disease | DRD3, PARK7, SLC6A3 | TAAR1 206/4885IDO1 523/4885SLC6A2 128/4885 |
| US-11744810-B2 | Methods of treating or preventing an attention disorder, cognitive disorder, and/or dementia associated with a neurodegenerative disorder | CHAT, COMT, SLC6A2 | TAAR1 590/4885IDO1 939/4885SLC6A2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.